Article Text

PDF
Early profiles of clinical evolution after intravenous thrombolysis in an unselected stroke population
  1. M G Delgado1,
  2. P Michel2,
  3. M Naves1,
  4. P Maeder3,
  5. M Reichhart2,
  6. M Wintermark4,
  7. J Bogousslavsky5
  1. 1Service of Neurology and Bone and Mineral Research Unit, Hospital Central de Asturias, Oviedo, Spain
  2. 2Service of Neurology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  3. 3Service of Radiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  4. 4Department of Radiology, Neuroradiology Section, University of California, San Francisco, California, USA
  5. 5Department of Neurology, Genolier Swiss Medical Network, Valmont-Genolier, Switzerland
  1. Correspondence to Dr Montserrat González Delgado, Servicio de Neurología, C/Celestino Villamil s/n, 33006 Oviedo, Spain; mglezdelgado{at}yahoo.es

Abstract

Background Intravenous recombinant tissular plasminogen activator (rt-PA) is the only approved pharmacological treatment for acute ischaemic stroke. The authors aimed to analyse potential causes of the variable effect on early course and late outcome.

Methods and results 136 patients (42% women, 58% men) treated with intravenous rt-PA within 3 h of stroke onset in an acute stroke unit over a 3-year period, were included. Early clinical profiles of evolution at 48 h were divided into clinical improvement (CI) (decrease >4 points in the National Institute of Health Stroke Scale (NIHSS)); clinical worsening (CW) (increase >4 points NIHSS); clinical worsening after initial improvement (CWFI) (variations of >4 points in the NIHSS). Patients with clinical stability (no NIHSS modification or <4 points) were excluded. The patients showed in 66.9% CI, 13.2% CW 8.1 % CWFI and 11.8% remained stable. Female sex, no hyperlipaemia and peripheral arterial disease were associated with CW. Male sex and smoking were associated with CI. Absence of arterial occlusion on admission (28.4%) and arterial recanalisation at 24 h were associated with CI. Main causes of clinical deterioration included symptomatic intracranial haemorrhage (sICH), persistent occlusion and cerebral oedema. 23.5% developed ICH, 6.6% of which had sICH. At 3 months, 15.5% had died. Mortality was increased in CW, mainly related to sICH and cerebral oedema. The outcome of CWFI was intermediate between CW and CI.

Conclusions Early clinical profiles of evolution in thrombolysed patients vary considerably. Even with CI, it is critical to maintain vessel permeability to avoid subsequent CW.

  • Fibrinolysis
  • cerebral ischaemia
  • thrombolysis

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the Commission D'Ethique de la Recherche Clinique, Université de Lausanne.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.